Barbara Bardoni Selected Research

RNA-Binding Proteins (RNA-Binding Protein)

1/2018	Modeling Fragile X Syndrome in Drosophila.
1/2018	HITS-CLIP in various brain areas reveals new targets and new modalities of RNA binding by fragile X mental retardation protein.
1/2018	New Insights Into the Role of Cav2 Protein Family in Calcium Flux Deregulation in Fmr1-KO Neurons.
1/2017	The Search for an Effective Therapy to Treat Fragile X Syndrome: Dream or Reality?
9/2015	The FMRP/GRK4 mRNA interaction uncovers a new mode of binding of the Fragile X mental retardation protein in cerebellum.
10/2014	Fragile X Syndrome: from molecular pathology to therapy.
1/2012	Intellectual disabilities, neuronal posttranscriptional RNA metabolism, and RNA-binding proteins: three actors for a complex scenario.
12/2011	A metabolomic and systems biology perspective on the brain of the fragile X syndrome mouse model.
5/2011	Functional characterization of the AFF (AF4/FMR2) family of RNA-binding proteins: insights into the molecular pathology of FRAXE intellectual disability.
8/2010	The role of G-quadruplex in RNA metabolism: involvement of FMRP and FMR2P.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Barbara Bardoni Research Topics

Disease

24	Fragile X Syndrome (Martin Bell Syndrome) 01/2022 - 06/2002
21	Intellectual Disability (Idiocy) 01/2021 - 09/2003
3	Autism Spectrum Disorder 01/2022 - 01/2021
3	Down Syndrome (Down's Syndrome) 01/2021 - 01/2012
3	Schizophrenia (Dementia Praecox) 01/2021 - 01/2017
3	Autistic Disorder (Autism) 01/2018 - 01/2014
2	Neurodevelopmental Disorders 01/2021 - 01/2019
2	Rett Syndrome (Rett's Disorder) 01/2021 - 01/2012
2	Fragile X Tremor Ataxia Syndrome 12/2019 - 05/2013
1	Epilepsy (Aura) 01/2017
1	Seizures (Absence Seizure) 01/2015
1	Facioscapulohumeral Muscular Dystrophy 03/2013
1	Neoplasms (Cancer) 07/2009
1	Cicatrix (Scar) 10/2004
1	Multiple Sclerosis 04/2004

Drug/Important Bio-Agent (IBA)

18	RNA-Binding Proteins (RNA-Binding Protein)IBA 01/2018 - 06/2002
14	Fragile X Mental Retardation ProteinIBA 01/2018 - 09/2003
7	RNA (Ribonucleic Acid)IBA 01/2018 - 01/2007
7	Proteins (Proteins, Gene)FDA Link 01/2017 - 04/2004
2	Type 2 Cyclic Nucleotide PhosphodiesterasesIBA 01/2022 - 01/2019
2	Messenger RNA (mRNA)IBA 12/2019 - 05/2013
2	3' Untranslated Regions (3' UTR)IBA 01/2015 - 05/2013
1	Guanosine Monophosphate (5' Guanylic Acid)IBA 01/2022
1	Adenosine Monophosphate (AMP)IBA 01/2022
1	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 01/2021
1	CalciumIBA 01/2021
1	Inositol (Myoinositol)IBA 01/2021
1	diethylstilbestrol monophosphate (PDES)IBA 01/2021
1	Cholecystokinin Receptors (Cholecystokinin Receptor)IBA 01/2021
1	Cadherins (E-Cadherin)IBA 01/2021
1	Small Interfering RNA (siRNA)IBA 12/2019
1	5' Untranslated Regions (5' UTR)IBA 12/2019
1	Peptides (Polypeptides)IBA 12/2019
1	NucleotidesIBA 01/2019
1	Eukaryotic Initiation Factor-4EIBA 01/2017
1	Peptide Initiation Factors (Initiation Factor)IBA 01/2017
1	Carisoprodol (Soma)FDA LinkGeneric 01/2015
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2015
1	Protein Isoforms (Isoforms)IBA 03/2013
1	ElementsIBA 07/2009
1	Drosophila ProteinsIBA 10/2004
1	DNA (Deoxyribonucleic Acid)IBA 04/2004

Therapy/Procedure

5	Therapeutics 01/2021 - 10/2014
1	Cognitive Training 01/2018